Rebecca is a versatile CEO and board director with twenty-five years of experience in drug development, manufacturing and leadership. Her experience spans a wide range of therapeutic areas and platforms in large pharma and small biotech. She currently serves as a biotechnology board member and advisor, including on the boards of Halda Therapeutics, Octant, and Artelis Biopharma. Most recently she served as President and CEO of Siduma Therapeutics. She has previously held key operational leadership roles in emerging biotech companies including EvolveImmune Therapeutics, Cardurion Pharmaceuticals and Prevail Therapeutics. Prior to these roles, she spent eleven years working in medical affairs, development, corporate affairs and manufacturing at Alexion Pharmaceuticals where she led successful development programs, integrations and global enterprise projects. Earlier in her career she worked in development and medical affairs at Novartis Pharmaceuticals and was an Assistant Professor at Northeastern University.

Outside of her operating and advising roles Rebecca also works with organizations that are preparing our ecosystems for future growth. She is on the board of Latinos in Bio and the advisory board of the Northeastern University Bouvé College of Health Sciences.

Rebecca earned a Doctorate in Pharmacy from Northeastern University and completed her post-doctoral clinical research fellowship at Tufts Medical Center in the field of organ transplant therapeutics. She additionally holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management.